Summary of study ST001495

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR001013. The data can be accessed directly via it's Project DOI: 10.21228/M8RH7J This work is supported by NIH grant, U2C- DK119886.


Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  |  Download all metabolite data  |  Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data (Contains raw data)
Study IDST001495
Study TitleEffects of Synbiotic Administration on Fecal Microbiome and Metabolomic Profiles of Dogs receiving Antibiotics
Study Typeuntargeted metabolomics
Study SummaryEffect of antibiotics on fecal microbiome and metabolome
University of California, Davis
DepartmentCollege of Biological Sciences
LaboratoryWest Coast Metabolomics Center
Last NamePaglia
First NameKelly
Address451 Health Sciences Drive, Room 1313
Submit Date2020-09-24
Raw Data AvailableYes
Raw Data File Type(s).cdf
Analysis Type DetailGC-MS
Release Date2020-10-13
Release Version1
Kelly Paglia Kelly Paglia application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR001013
Project DOI:doi: 10.21228/M8RH7J
Project Title:Effects of Synbiotic Administration on Fecal Microbiome and Metabolomic Profiles of Dogs receiving Antibiotics
Project Type:Double-blind randomized controlled trial
Project Summary:The purpose of this study was to compare the fecal microbiome and metabolome of dogs administered enrofloxacin and metronidazole, followed by either a placebo or a bacterial/yeast synbiotic combination, for 21 days with reevaluation 8 weeks after treatment. Fecal samples were collected on days 5-7 (baseline), 26-28, and 82-84. The fecal microbiome was analyzed by qPCR and sequencing of 16S rRNA genes; time-of-flight mass spectrometry was used to determine metabolomic profiles. Split plot repeated measures ANOVAs were used to compare results between treatment groups. P < 0.05 was considered significant, with Benjamini & Hochberg’s False Discovery Rate used to adjust for multiple comparisons. Alpha diversity metrics differed significantly over time in both treatment groups, with incomplete recovery by days 82-84. Beta diversity and the dysbiosis index differed significantly over time and between treatment groups, with incomplete recovery at days 82-84 for dogs in the placebo group. Significant group-by-time interactions were noted for 15 genera, including Adlercreutzia, Bifidobacterium, Slackia, Turicibacter, Clostridium, [Ruminococcus], Erysipelotrichaceae_g_, [Eubacterium], and Succinivibrionaceae_g_. Group and time effects were present for six genera, including Collinsella, Ruminococcaceae_g_, and Prevotella. Metabolite profiles differed significantly by group-by-time, group, and time for 28, 20, and 192 metabolites, respectively. These included short-chain fatty acid, bile acid, tryptophan, sphingolipid, benzoic acid, and cinnaminic acid metabolites, as well as fucose and ethanolamine. Changes in many taxa and metabolites persisted through days 82-84.
Institute:University of Tennessee
Department:College of Veterinary Medicine
Laboratory:Small Animal Clinical Sciences
Last Name:Whittemore
First Name:Jacqueline
Address:2407 River Drive, Knoxville TN 37996
Funding Source:Nutramax Laboratories Veterinary Sciences, Inc., Lancaster, SC